Objective: Four breast cancer subtypes defined by immunohistochemistry (IHC) expression of estrogen receptor (ER) or progesterone receptor (PR) and human epidermal growth factor receptor 2 (Her2) are ER/PR+,Her2+; ER/PR+,Her2-; ER/PR-,Her2+; and ER/PR-,Her2-.
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ver the last few decades there have been outstanding advances in breast cancer management leading to earlier detection of disease and the development of more effective treatments resulting in significant declines in breast cancer deaths and improved outcomes for women living with the disease. 1,2 Breast cancer is no longer seen as a single disease but rather a multifaceted disease comprised of distinct biological subtypes with diverse natural history, presenting a varied spectrum of clinical, pathologic, and molecular features with different prognostic and therapeutic implications. Consensus regarding the definitive prognostic/predictive analysis has yet to be reached, but significant progress continues to be made in the ongoing search for a specific, rigorous and reproducible method of identifying successful treatment algorithms utilizing biological markers.
Recent attentions have been directed singularly at molecular classifications of breast cancer. [3] [4] [5] [6] [7] [8] [9] [10] [11] While molecular and genetic testing is very "elegant," prognostic and predictive, it is expensive
and not yet widely available. Also, despite the prognostic information provided by the molecular test, current reports of assay results impart little specific guidance of response to targeted and proven therapy; for example, endocrine and trastuzumab therapy for tumors expressing estrogen receptor/progesterone receptor (ER/PR) or human epidermal growth factor receptor 2 (Her2)
proteins, respectively. The immunohistochemistry (IHC) classification provides both therapeutic and prognostic information.
In this study breast cancer is classified into four groups based on IHC profile ER/PR and Her2/neu expression, positive (+) and/or negative (-). The groups are:
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• ER/PR+,Her2-= ER+/PR+,Her2-; ER-/PR+,Her2-; ER+/PR-,Her2-
• ER/PR-,Her2+ = ER-/PR-,Her2+
• ER/PR-,Her2-= ER-/PR-,Her2-
The IHC classification correlates well with intrinsic gene expression microarray categorization:
ER/PR+,Her2+ with Luminal B; ER/PR+,Her2-with Luminal A; ER/PR-,Her2+ and ER/PR-,Her2-with triple negative/basal-like tumors. 1 Apart from lending itself to subtype analyses of tumor when fresh tissue is not available, the IHC classification has prognostic and therapeutic implications, is inexpensive and readily available.
SUBJECTS AND METHODS

Study Population
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nuclei is considered positive. Staining of 5% to 19% of tumor cell nuclei is considered borderline. Staining of <5% of tumor cell nuclei is considered negative (table 1) . For the purpose of the study both borderline and overtly positive results were considered positive.
Her2 neu
Her2 neu results were obtained from the cancer registry as available or from the medical record.
The clone used was a polyclonal (Her2 HercepTest Kit) and the detection system used was a 
STATISTICAL ANALYSIS
Differences in subjects and tumor characteristics between the various breast cancer subtypes were analyzed using analysis of variance for continuous variables and chi-square test for categorical variables. The Kaplan-Meier product limit method was used to estimate the overall and disease-free survival. Ninety-five percent confidence intervals (CI) for the percentage surviving at a particular time were estimated using the logit transformation. Overall survival was measured from the date of diagnosis to the date of death from any cause. Disease-free survival was measured from the date of first definitive treatment to the date of first relapse or death from
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Cox-proportional hazard model was used to estimate the hazard ratios and 95% CI for overall and disease-free survival between the breast cancer subtypes adjusting for age, lymph node status and disease stage. S-plus statistical software was used for survival analysis and SAS 9.1 (SAS Institute, Cary, NC, USA) was used for all other analyses. A P-value of <0.05 was considered statistically significant. The Kaplan-Meier curve for overall and disease-free survival by tumor subtype is shown in figure 1 . In the Cox regression analysis, subjects with the triple negative subtype, ER/PR-,Her2-had the worst overall survival (hazard ratio, 1.8; 95% CI, 1.0-3.0) and worst disease-free survival (hazard ratio, 1.5; 95% CI, 0.8-3.0) when compared with subjects with ER/PR+,Her2-subtype ( 14 Recently it was shown in a retrospective analysis that ER/PR+,Her2-tumor may benefit less from taxanes in the adjuvant setting. 15 We have classified breast cancer using IHC into 4 global subtypes out of the 8 possible subtypes commonly used by other authors. 16 We believe this classification is practical, simple, informative, clinically useful, and quite discriminative between the subtypes. The other four groups will emerge if we differentiate based on PR expression (ER+/PR+ vs. ER+/PR-tumors).
RESULTS
Final analysis included 1134 invasive breast cancer subjects identified in the Marshfield
The independent prognostive and predictive role of PR expression irrespective of ER has been a subject of great controversy as demonstrated by the report from the ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant trial, a large worldwide trial comparing the efficacy of tamoxifen with that of the aromatase inhibitor anastrazole, showing overall that patients with ER+/PR+ tumors had a lower recurrence rate than those with ER+/PR-tumors. 17 The observation from the same study that patients with ER+/PR-tumors respond nearly as well to anastrozole as those with ER+/PR+ tumors suggests that the ER signaling pathway is functional in many ER+/PR-tumors, consistent with the well-known fact that the PR gene is regulated by the estrogen pathway.
Breast Cancer Subtypes Page 12 observed in the BIG 1-98 trial which is the largest study of an aromatase inhibitor as up-front adjuvant therapy for early breast cancer. 18 Studies that have been classified as using more than 4 subtypes are plagued by these controversies and those inherent in small sample size and multiplicity of variables. 19, 20 Recent publications have shown that newer molecular classification of breast cancer also has important prognostic value. Subtyping breast cancer using microarrays for gene expression analysis is the best way to perform such molecular classification. ER/PR-,Her2+ (ER-/Her2+); and ER/PR-,Her2-with triple negative/basal-like tumors. 3, 13 It is worth noting that the reliability of the ER/PR and Her2 testing is imperfect. There is substantial intralaboratory and interlaboratory variation in ER results because fixation, antigen retrieval, and staining methods may differ among laboratories. [21] [22] [23] Substantial discordance among Her2 results generated in different laboratories from the same specimen has also been reported. 12, 21, 24 For this classification to be more helpful, ongoing efforts 12 should also be directed at standardization of current testing and development of more reliable and reproducible testing for ER/PR and Her2/neu expression. 12, [21] [22] [23] [24] Breast Cancer Subtypes Page 13
In our current analysis we have not considered the semi-quantitative information from IHC in terms of ER/PR or Her2 levels of expression on clinical outcomes largely because we do not have adequate sample for such analysis. We believe such subsetting within the subtypes may be unreliable with regards to the message highlighted in this study due to inadequate sample size.
This study of a predominantly Caucasian population reports the distribution of subtypes as different from that seen in a predominantly African American population where ER/PR-,Her2-is more prevalent (39% premenopausal versus 14% postmenopausal African American women versus 16% non-African American women of all ages). 3 Also of note, 80% of our subjects are An investigation of all subgroups showed benefit from chemotherapy, but after controlling for age, tumor size, and lymph node status, the sample size was not sufficient to make a strong assertion except in the ER/PR+,Her2-subgroup. In the ER/PR+,Her2-subgroup (781 subjects), 524 patients did not receive chemotherapy and 257 patients did receive chemotherapy.
Chemotherapy conferred overall and disease-free survival advantages (P = 0.003 and 0.009, respectively).
This study supports other studies 3, 13, 25 is reasonable to assume that trastuzumab and lapatinib will shift the Her2+ curve upward (Her2+/ER-). We lack targeted therapies for triple negative breast cancer and this continues to direct the focus of ongoing research. [26] [27] [28] Despite the enormous effort and funding channeled towards molecular diagnostics, there is still individual patients by these tests, 14 suggesting that they are probably tracking a common set of biologic phenotypes which are heavily weighted toward ER/PR and Her2 gene pathways.
Finally, the superiority of molecular technology over IHC testing is theoretical and based on the premise that molecular technology provides quantization and reproducibility. This presumptive theory is the basis for some ongoing studies but is yet to be proven.
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CONCLUSIONS
Our study showed the triple negative subtype (ER/PR-,Her2-) has the worst overall and diseasefree survival compared to the other subtypes. Further confirmatory studies are necessary to refine IHC classification. We support IHC classification as a clinical tool as ER/PR and Her2-testing is widely available at a reasonable cost, is a clinically-used therapeutically informative classification of breast cancer based on immunophenotype/biologic phenotypes, and is prognostic as well as somewhat predictive. Additional ongoing efforts 12 should be directed at standardization of current testing methods and development of more reliable and reproducible testing.
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